Kenvue Inc.
Kenvue Announces 2023 Full Year and Q4 Financial Results
Summary
Kenvue Inc. reported its financial results for the fiscal full year and fourth quarter ended December 31, 2023. The company saw a net sales increase of 3.3% for the full year to $15.4 billion, with organic growth of 5.0%. However, the fourth quarter saw a net sales decrease of 2.7% to $3.7 billion with organic growth of -2.4%. The full-year diluted earnings per share were $0.90, and adjusted diluted earnings per share were $1.29. The company expects full-year 2024 net sales growth in the range of 1.0% to 3.0%.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement